Background: Cancer clinical trials (CCT) offer significant potential benefit, not only for future patients but also for enrolled participants, yet a very small minority of cancer patients participate, resulting in low levels of enrollment that have stalled clinical trials dramatically. Though many have endeavored to study this phenomenon, relatively little research has explored the demographic factors which may affect CCT enrollment. Understanding patient demographics is critical to optimizing enrollment, evaluating generalizability, and ensuring equity of CCT.
Methods: To better understand the effect of social determinants of health on CCT enrollment, the authors constructed a multivariable logistic regression model to analyze data collected in the last ten years in the CDC Behavioral Risk Factor Surveillance System (BRFSS) Survey, an annual national survey conducted among the non-institutionalized adult population of the U.S.
Results: In multivariable regression analysis, enrollment varied significantly with sociodemographic factors. Individuals of higher income, Hispanic ethnicity, and younger age were most likely to participate in CCTs. Enrollment did not vary significantly by educational attainment.
Conclusion: Our multivariable analysis indicated people of color are more likely to participate in CCT, perhaps demonstrating that structural barriers shape participation more than race alone. Efforts to improve CCT enrollment may benefit from a shift in focus towards access to care by alleviating structural and financial barriers to enrollment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872971 | PMC |
http://dx.doi.org/10.1016/j.conctc.2021.100718 | DOI Listing |
Discov Oncol
January 2025
Division of Hematology/Oncology, The University of Texas Health Sciences Center at Houston, McGovern Medical School, 6431 Fannin Street, MSB 5.216, Houston, TX, 77030, USA.
The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment.
View Article and Find Full Text PDFDis Esophagus
January 2025
Department of Digestive and Oncological Surgery, Claude Huriez Hospital, Chu Lille, Lille, France.
Background: Malnutrition is common with esophagogastric cancers and is associated with negative outcomes. We aimed to evaluate if immunonutrition during neoadjuvant treatment improves patient's health-related quality of life (HRQOL) and reduces postoperative morbidity and toxicities during neoadjuvant treatment.
Methods: A multicenter double-blind randomized controlled trial (RCT) was undertaken.
J Infect Dev Ctries
December 2024
Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Introduction: The objective of this study was to assess the effectiveness of ivermectin and colchicine as treatment options for coronavirus disease 2019 (COVID-19).
Methodology: A three-arm randomized controlled clinical trial was conducted in the Triage Clinic of the family medicine department at Ain Shams University Hospitals on participants who had been diagnosed with moderate COVID-19. Patients aged < 18 years or > 65 years, with any co-morbidities, pregnant or lactating females, and those with mild or severe COVID-19 confirmed cases were excluded.
J Infect Dev Ctries
December 2024
Students' Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Introduction: Inflammation plays a role in coronavirus disease 2019 (COVID-19) pathophysiology and anti-inflammatory drugs may help reduce the disease severity. Levamisole is an anthelmintic drug with immunomodulatory and possible antiviral effects. This study aimed to evaluate the role of levamisole in the treatment of patients with COVID-19.
View Article and Find Full Text PDFVirol J
January 2025
Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518118, China.
Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!